Is UNII-NY22HMQ4BX Safe in Breastfeeding
Question
I am a breastfeeding mother and i want to know if it is safe to use UNII-NY22HMQ4BX? Is UNII-NY22HMQ4BX safe for nursing mother and child? Does UNII-NY22HMQ4BX extracts into breast milk? Does UNII-NY22HMQ4BX has any long term or short term side effects on infants? Can UNII-NY22HMQ4BX influence milk supply or can UNII-NY22HMQ4BX decrease milk supply in lactating mothers?
UNII-NY22HMQ4BX lactation summary
- DrLact safety Score for UNII-NY22HMQ4BX is 7 out of 8 which is considered Dangerous as per our analyses.
- A safety Score of 7 indicates that usage of UNII-NY22HMQ4BX may cause toxic or severe side effects in breastfed baby.
- Our study of different scientific research indicates that UNII-NY22HMQ4BX may cause moderate to high side effects or may affect milk supply in lactating mother.
- Our suggestion is to use safer alternate options rather than using UNII-NY22HMQ4BX .
- Usage of UNII-NY22HMQ4BX is in contradiction to breastfeeding hence if it is must to use UNII-NY22HMQ4BX and there is no better alternative available then breastfeeding shall be stopped permanently or temporarily.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
Answer by Dr. Ru: About UNII-NY22HMQ4BX usage in lactation
Steroidal aromatase inhibitor. Using this drug while breastfeeding in not recommended
Answer by DrLact: About UNII-NY22HMQ4BX usage in lactation
No information is available on the use of UNII-NY22HMQ4BX during breastfeeding. Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy. The manufacturer recommends that breastfeeding be discontinued during UNII-NY22HMQ4BX therapy and for 1 month after the last dose.
Alternate Drugs
Cetuximab(Unsafe)
Mercaptopurine(Safe)
Carboplatin(Dangerous)
Hydroxyurea(Low Risk)
Gemcitabine(Dangerous)
Paclitaxel(Dangerous)
Etoposide(Dangerous)
Fluorouracil(Dangerous)
Nivolumab(Unsafe)
Doxorubicin(Dangerous)
Alemtuzumab(Low Risk)
Vinblastine(Dangerous)
Cyclophosphamide(Dangerous)
Rituximab(Low Risk)
Bleomycin(Dangerous)
Docetaxel(Dangerous)
Cisplatin(Unsafe)
Bevacizumab(Low Risk)
Vinorelbine(Dangerous)
Busulfan(Dangerous)
Pazopanib(Unsafe)
Dacarbazine(Dangerous)
Trastuzumab(Unsafe)
Imatinib(Unsafe)
Thioguanine(Dangerous)
Cladribine(Dangerous)
Letrozole(Dangerous)
Azelaic Acid(Safe)
Erlotinib(Unsafe)
Dasatinib(Unsafe)
Exemestane(Dangerous)
Vincristine(Dangerous)
Dactinomycin(Dangerous)
Nilotinib(Unsafe)
Tamoxifen(Dangerous)
Ipilimumab(Unsafe)
Mitoxantrone(Dangerous)
Letrozole(Dangerous)
Exemestane(Dangerous)